# Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

> **NCT04262869** · PHASE2 · WITHDRAWN · sponsor: **Emory University**

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Stage IIIB Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Carboplatin
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04262869
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-27
- **Primary completion:** 2021-10-18
- **Final completion:** 2021-10-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to accrual issues
- **Last updated:** 2021-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262869, "Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04262869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*